In a landmark Phase 2 obesity trial, participants receiving the highest dose achieved: Up to ~24% average weight loss at 48 weeks Weight loss had not yet plateaued at the end of the study Potential for even greater reductions with longer treatment duration For context: Semaglutide (GLP-1): ~15% weight loss Tirzepatide (GIP + GLP-1): ~2123% weight loss Retatrutide (GIP + GLP-1 + Glucagon): ~24%+ weight loss in Phase 2 studies Common side effects were similar to other GLP-1based therapies and included nausea, vomiting, diarrhea, constipation, and abdominal discomfort, primarily during dose escalation
Any visceral fat reduction benefits specific to the GH pathway would gradually diminish, but overall weight loss from retatrutide would continue
Treatment with exenatide (or phosphate-buffered saline as control group) was initiated 5 min before the onset of reperfusion and then continued for 2 days
As with other incretin-based therapies, the most frequently reported side effects of retatrutide particularly in the early stages of treatment are gastrointestinal in nature
In their systematic review, Athanasiadis et al
At Luxury Lounge Aesthetics & IV Wellness, we understand the multifaceted challenges of weight loss, especially for those with pre-existing medical conditions that lead to obesity
